A short clip from an obesity doctor with advice aimed at anyone on a GLP-1. The habit itself isn't named until you watch.
Recap by typeshit. Video by @drspencer on TikTok.
The Form 483 cites microbial growth in a clean hood, reversed cleanroom air pressure and active ingredients marked for research use only. Check which pharmacy filled your vial.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
MedPage's endocrinology roundup also has petrelintide phase II weight loss of up to 9.2% and over 100,000 new oral Wegovy scripts in two months.
The drug behind Mounjaro and Zepbound slowed tumors in an early mouse study. Obesity is tied to higher breast cancer risk, especially after menopause, so the work is drawing interest.
Loading…